CAJ | 학술논문

目的：研究晚期肺腺癌EGFR突变状态对培美曲塞疗效的影响。方法：收集经病理学确诊且有可评价病灶的晚期肺腺癌患者40例，所有病例均有表皮生长因子受体（epidermal growth factor receptor，EGFR）突变状态检测结果，均采用含培美曲塞方案化疗，以总有效率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）为研究终点进行回顾性分析，比较两组间的疗效差异。结果：EGFR野生组和突变组总有效率分别为44.4%（8/18）和31.8%（7/22）（P=0.412），疾病控制率分别为88.9%（16/18）和81.8%（18/22，P=0.673）。EGFR野生组中位PFS较突变组延长（8.9 vs.5.3个月，P=0.046）。结论：晚期肺腺癌EGFR突变状态对培美曲塞的疗效有影响。
목적：연구만기폐선암EGFR돌변상태대배미곡새료효적영향。방법：수집경병이학학진차유가평개병조적만기폐선암환자40례，소유병례균유표피생장인자수체（epidermal growth factor receptor，EGFR）돌변상태검측결과，균채용함배미곡새방안화료，이총유효솔（ORR）、질병공제솔（DCR）、무진전생존기（PFS）위연구종점진행회고성분석，비교량조간적료효차이。결과：EGFR야생조화돌변조총유효솔분별위44.4%（8/18）화31.8%（7/22）（P=0.412），질병공제솔분별위88.9%（16/18）화81.8%（18/22，P=0.673）。EGFR야생조중위PFS교돌변조연장（8.9 vs.5.3개월，P=0.046）。결론：만기폐선암EGFR돌변상태대배미곡새적료효유영향。
Objective:To assess the role of EGFR mutations on pemetrexed response in patients with advanced lung adenocarcino-ma. Method: Forty pulmonary adenocarcinoma patients with evaluable lesions were retrospectively screened .They had been treated with pemetrexed-included chemotherapy and had EGFR gene test results. The evaluation endpoints were overall response rate,disease control rate and progression free survival. Result:No significant statistical difference was seen in overall response rate(ORR) (44.4%VS 31.8%, respectively) and disease control rate(DCR) (88.9%VS 81.8%, respectively ) between EGFR wild group and EGFR muta-tion group, but patients in EGFR wild group had longer progression free survival(PFS) ( 8.9 months VS 5.3 months;P=0.046). Conclu-sion:EGFR mutation status can influence the efficacy of pemetrexed.